Aliskiren reduces portal pressure in cirrhotic rats

Liver International

Volumn 32, Issue 4, 2012, Pages 692-693

  Chang, Ching Chih ^a,b   Huang, Hui Chun ^a,b   Lee, Wen Shin ^a,b   Wang, Sun Sang ^a,b   Lee, Fa Yauh ^a,b   Lin, Han Chieh ^a,b   Nong, Jing Yi ^a   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALISKIREN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART RATE; LETTER; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; RAT;

AMIDES; ANIMALS; BILE DUCTS; BLOOD PRESSURE; BODY WEIGHT; FUMARATES; HEMODYNAMICS; HYPERTENSION, PORTAL; LIGATION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84858291878     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02695.x     Document Type: Letter

References (8)

1. Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005; 54: 1790-6.
2. Bataller R, Ginès P, Nicolás JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
3. Westermann D, Schmieder R, Schultheiss HP, et al. Renin inhibitors, clinical experience. J Mol Med 2008; 86: 691-5.
4. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52: 1068-75.
5. Vaidyanathan S, Warren V, Yeh C, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47: 192-200.
6. Debernardi-Venon W, Martini S, Biasi F, et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-33.
7. Schepke M, Werner E, Biecker E, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389-95.
8. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-404.